Together, pharmacological inhibition—through canonical NF-κB pathway activity inhibitor JSH-23 or signalling inhibitor QNZ (EVP4593)—did not significantly suppress RAP tumour-induced lethality below toxic levels. Here, NFKB1 is linked to neoplasm.